Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Transarterial Radioembolization (TARE) with Y-loaded glass microspheres is a locoregional treatment option for Hepatocellular Carcinoma (HCC). Post-treatment Y bremsstrahlung imaging using Single-Photon Emission Tomography (SPECT) is currently a gold-standard imaging modality for quantifying the delivered dose. However, the nature of bremsstrahlung photons causes difficulty for dose estimation using SPECT imaging. This work aimed to investigate the possibility of using glass microspheres loaded with Y and Nanoparticles (NPs) to improve the quantification of delivered doses.
Methods: The Monte Carlo codes were used to simulate the post-TARE Y planar imaging. Planar images from bremsstrahlung photons and characteristic X-rays are acquired when 0, 1.2 mol/L, 2.4 mol/L, and 4.8 mol/L of Gold (Au), Hafnium (Hf), and Gadolinium (Gd) NPs are incorporated into the glass microspheres. We evaluated the quality of acquired images by calculating sensitivity and Signal-to-Background Ratio (SBR). Therapeutic effects of NPs were evaluated by calculation of Dose Enhancement Ratio (DER) in tumoral and non-tumoral liver tissues.
Results: The in silico results showed that the sensitivity values of bremsstrahlung and characteristic X-ray planar images increased significantly as the NPs concentration increased in the glass microspheres. The SBR values decreased as the NPs concentration increased for the bremsstrahlung planar images. In contrast, the SBR values increased for the characteristic X-ray planar images when Hf and Gd were incorporated into the glass microspheres. The DER values decreased in the tumoral and non-tumoral liver tissues as the NPs concentration increased. The maximum dose reduction was observed at the NPs concentration of 4.8 mol/L (≈ 7%).
Conclusions: The incorporation of Au, Hf, and Gd NPs into the glass microspheres improved the quality and quantity of post-TARE planar images. Also, treatment efficiency was decreased significantly at NPs concentration > 4.8 mol/L.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12149-022-01727-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.
Cardiovasc Intervent Radiol
September 2025
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: To evaluate predictors of outcomes in colorectal liver metastases (CLM) patients undergoing 90Y radioembolization (TARE), focusing on the impact of tumor absorbed dose.
Materials And Methods: Patients' characteristics and dosimetry assessments were analyzed in 231 patients undergoing 329 TARE sessions from 09/2009 to 07/2023. Response was assessed using RECIST1.
On the transverse relaxation enhancement effect in H-MRI of the lung.
Magn Reson Imaging
September 2025
Julius-Maximilians-Universität Würzburg, Department of Experimental Physics 5, Germany.
Purpose: Presenting a technique to quantify the transverse relaxation time T, which is associated with the diffusion of water molecules through the internal magnetic field gradients of the lung in-vivo.
Methods: A Half-Fourier-Acquired Single-shot Turbo spin-Echo (HASTE) pulse sequence with Hahn-echo preparation was implemented and used for image acquisition. Quantification of T was performed by acquiring multiple images with identical TE, but with a different number of refocusing pulses between excitation and signal acquisition.
Phosphorus-32 microspheres: A dual-modality transarterial radioembolization approach for hepatocellular carcinoma therapy and Anti-PD1 immunotherapy potentiation.
Mater Today Bio
October 2025
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing, China.
Transarterial radioembolization (TARE) is a key therapy for hepatocellular carcinoma (HCC) management and downstaging. While Y microspheres (glass/resin) are widely used, their clinical application is limited by complexity, short half-life, and high costs. Thus, novel radionuclide microspheres are crucial.
View Article and Find Full Text PDFSolvent-free rubbing assembly of ordered porous silica microsphere monolayers to miniaturize planar chromatography screening.
J Chromatogr A
October 2025
Institute of Nutritional Science, Chair of Food Science, and Interdisciplinary Research Center, Justus Liebig University Giessen, Heinrich-Buff-Ring 26-32, 35392 Giessen, Germany; Center for Sustainable Food Systems, Justus Liebig University Giessen, Senckenbergstr. 3, 35390 Giessen, Germany. Electr
A novel concept for assembling ordered porous silica microsphere monolayers for screening in miniaturized planar chromatography is disclosed. It contributes to sustainability in chromatography by facilitating parallel sample separation, reducing volume consumption, enabling cost-effective layer fabrication, and promoting the feasibility of automation. The first step toward realizing the proposed concept has been taken.
View Article and Find Full Text PDFComparison of Dosimetry Models and Dose Thresholds for Predicting Pathologic Response to Yttrium-90 Radioembolization with Glass Microspheres.
Cardiovasc Intervent Radiol
August 2025
Department of Radiology, University of California San Diego, San Diego, CA, USA.
Purpose: This study evaluated pathologic response to ablative transarterial radioembolization (TARE) and compared single-compartment, mean tumor dose, and voxel-based dosimetry thresholds for hepatocellular carcinoma (HCC).
Materials And Methods: This is a retrospective, single-center study which included consecutive patients treated with glass microsphere TARE for a previously untreated HCC followed by liver transplantation between January 2015 - December 2024. A complete response (CR) was assigned if explant pathology showed complete pathologic necrosis (CPN) and if the patient had not undergone further treatments to the tumor.